Spyre Therapeutics (SYRE) Debt to Equity (2023 - 2025)
Historic Debt to Equity for Spyre Therapeutics (SYRE) over the last 3 years, with Q3 2025 value amounting to $0.02.
- Spyre Therapeutics' Debt to Equity fell 6795.65% to $0.02 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.02, marking a year-over-year decrease of 6795.65%. This contributed to the annual value of $0.05 for FY2024, which is 54121.39% up from last year.
- According to the latest figures from Q3 2025, Spyre Therapeutics' Debt to Equity is $0.02, which was down 6795.65% from $0.13 recorded in Q2 2025.
- Spyre Therapeutics' Debt to Equity's 5-year high stood at $0.13 during Q2 2025, with a 5-year trough of -$0.79 in Q2 2023.
- Over the past 3 years, Spyre Therapeutics' median Debt to Equity value was $0.02 (recorded in 2024), while the average stood at -$0.04.
- Over the last 5 years, Spyre Therapeutics' Debt to Equity had its largest YoY gain of 176377.18% in 2025, and its largest YoY loss of 6795.65% in 2025.
- Over the past 3 years, Spyre Therapeutics' Debt to Equity (Quarter) stood at $0.01 in 2023, then surged by 541.21% to $0.05 in 2024, then tumbled by 50.01% to $0.02 in 2025.
- Its last three reported values are $0.02 in Q3 2025, $0.13 for Q2 2025, and $0.09 during Q1 2025.